The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Lisocabtagene maraleucel for R/R MCL: TRANSCEND-NHL-001 update
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the TRANSCEND-NHL-001 study (NCT02631044), which is investigating lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL). The overall response to liso-cel was comparable to that seen with brexucabtagene autoleucel (brexu-cel), and liso-cel also demonstrated a reduction in toxicity, suggesting that this agent could be used as an alternative option for patients who are unable to be treated with brexu-cel. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
